1
|
Ernst J, Storch KF, Tran AT, Gabriel MM, Leotescu A, Boeck AL, Huber MK, Abu-Fares O, Bronzlik P, Götz F, Worthmann H, Schuppner R, Grosse GM, Weissenborn K. Advancement of door-to-needle times in acute stroke treatment after repetitive process analysis: never give up! Ther Adv Neurol Disord 2022; 15:17562864221122491. [PMID: 36147621 PMCID: PMC9486271 DOI: 10.1177/17562864221122491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2022] [Accepted: 08/05/2022] [Indexed: 11/21/2022] Open
Abstract
Background: In acute ischemic stroke, timely treatment is of utmost relevance.
Identification of delaying factors and knowledge about challenges concerning
hospital structures are crucial for continuous improvement of process times
in stroke care. Objective: In this study, we report on our experience in optimizing the door-to-needle
time (DNT) at our tertiary care center by continuous quality
improvement. Methods: Five hundred forty patients with acute ischemic stroke receiving intravenous
thrombolysis (IVT) at Hannover Medical School were consecutively analyzed in
two phases. In study phase I, including 292 patients, process times and
delaying factors were collected prospectively from May 2015 until September
2017. In study phase II, process times of 248 patients were obtained from
January 2019 until February 2021. In each study phase, a new clinical
standard operation procedure (SOP) was implemented, considering previously
identified delaying factors. Pre- and post-SOP treatment times and delaying
factors were analyzed to evaluate the new protocols. Results: In study phase I, SOP I reduced the median DNT by 15 min. The probability to
receive treatment within 30 min after admission increased by factor 5.35
[95% confidence interval (CI): 2.46–11.66]. Further development of the SOP
with implementation of a mobile thrombolysis kit led to a further decrease
of DNT by 5 min in median in study phase II. The median DNT was 29
(25th–75th percentiles: 18–44) min, and the probability to undergo IVT
within 15 min after admission increased by factor 4.2 (95% CI: 1.63–10.83)
compared with study phase I. Conclusion: Continuous process analysis and subsequent development of targeted workflow
adjustments led to a substantial improvement of DNT. These results
illustrate that with appropriate vigilance, there is constantly an
opportunity for improvement in stroke care.
Collapse
Affiliation(s)
- Johanna Ernst
- Department of Neurology, Hannover Medical School, Carl-Neuberg Strasse 1, Hannover 30625, Lower Saxony, Germany
| | - Kai F Storch
- Department of Neurology, Hannover Medical School, Hannover, Germany.,Department of Anesthesiology, Hannover Medical School, Hannover, Germany
| | - Anh Thu Tran
- Department of Neurology, Hannover Medical School, Hannover, Germany
| | - Maria M Gabriel
- Department of Neurology, Hannover Medical School, Hannover, Germany
| | - Andrei Leotescu
- Department of Neurology, Hannover Medical School, Hannover, Germany
| | - Anna-Lena Boeck
- Department of Neurology, Hannover Medical School, Hannover, Germany
| | - Meret K Huber
- Department of Neurology, Hannover Medical School, Hannover, Germany
| | - Omar Abu-Fares
- Department of Neuroradiology, Hannover Medical School, Hannover, Germany
| | - Paul Bronzlik
- Department of Neuroradiology, Hannover Medical School, Hannover, Germany
| | - Friedrich Götz
- Department of Neuroradiology, Hannover Medical School, Hannover, Germany
| | - Hans Worthmann
- Department of Neurology, Hannover Medical School, Hannover, Germany
| | - Ramona Schuppner
- Department of Neurology, Hannover Medical School, Hannover, Germany
| | - Gerrit M Grosse
- Department of Neurology, Hannover Medical School, Hannover, Germany
| | | |
Collapse
|
2
|
Huber MK, Raichle C, Lingor P, Synofzik M, Borgmann S, Erber J, Tometten L, Rimili W, Dolff S, Wille K, Knauss S, Piepel C, Lanznaster J, Rieg S, Prasser F, Pilgram L, Spottke A, Klockgether T, Klein C, Hopfner F, Höglinger GU. Outcomes of SARS-CoV-2 Infections in Patients with Neurodegenerative Diseases in the LEOSS Cohort. Mov Disord 2021; 36:791-793. [PMID: 33638915 PMCID: PMC8014567 DOI: 10.1002/mds.28554] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Revised: 02/05/2021] [Accepted: 02/08/2021] [Indexed: 01/18/2023] Open
Affiliation(s)
- Meret K Huber
- Department of Neurology, Hannover Medical School, Hannover, Germany
| | | | - Paul Lingor
- Department of Neurology, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.,German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
| | - Matthis Synofzik
- Department of Neurodegenerative Diseases, Centre for Neurology and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.,German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany
| | - Stefan Borgmann
- Department of Infectious Diseases and Infection Control, Hospital of Ingolstadt, Ingolstadt, Germany
| | - Johanna Erber
- School of Medicine, University Hospital Rechts der Isar, Technical University of Munich, Munich, Germany
| | - Lukas Tometten
- Department I for Internal Medicine, University Hospital of Cologne, University of Cologne, Cologne, Germany
| | - Wolfgang Rimili
- Department of Internal Medicine, Stiftung Kreuznacher Diakonie, Rhaunen, Germany
| | - Sebastian Dolff
- Department of Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Kai Wille
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, UKRUB, University of Bochum, Minden, Germany
| | - Samuel Knauss
- Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, Berlin, Germany
| | - Christiane Piepel
- Department of Hemato-Oncology and Infectious Diseases, Klinikum Bremen-Mitte, Bremen, Germany
| | - Julia Lanznaster
- Department of Internal Medicine, Hospital Passau, Passau, Germany
| | - Siegbert Rieg
- Medical Center-University of Freiburg, Division of Infectious Diseases, Department of Medicine II, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Fabian Prasser
- Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany
| | - Lisa Pilgram
- Department of Internal Medicine, Hematology and Oncology, Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Annika Spottke
- German Center for Neurodegenerative Diseases, Bonn, Germany.,Department of Neurology, University of Bonn, Bonn, Germany
| | - Thomas Klockgether
- German Center for Neurodegenerative Diseases, Bonn, Germany.,Department of Neurology, University of Bonn, Bonn, Germany
| | - Christine Klein
- Institute of Neurogenetics, University of Lübeck, Lübeck, Germany
| | | | - Günter U Höglinger
- Department of Neurology, Hannover Medical School, Hannover, Germany.,German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
| | | |
Collapse
|